What is Mendor?
Mendor operates at the intersection of hardware innovation and software-driven patient care. The company specializes in the design and development of advanced diabetes management products, most notably its portable 3G blood glucose meter. By pairing high-precision hardware with intuitive web-based software, Mendor addresses the critical need for seamless, daily glucose monitoring. Their product ecosystem is built upon a foundation of user-centric design, developed in close collaboration with diabetes experts to ensure that the technology effectively mitigates the complexities of chronic condition management. As a key player in the European medtech space, Mendor continues to bridge the gap between clinical accuracy and patient accessibility.
How much funding has Mendor raised?
Mendor has raised a total of $145.6M across 4 funding rounds:
Series B
$11.6M
Private Equity
$6.4M
Debt
$8.8M
Private Equity
$118.8M
Series B (2011): $11.6M with participation from Finnvera Venture Capital, Life Sciences Partners, and Finnish Industry Investment
Private Equity (2014): $6.4M led by Finnvera Venture Capital, Life Sciences Partners, and Finnish Industry Investment
Debt (2014): $8.8M supported by IPF Partners
Private Equity (2016): $118.8M featuring IPF Partners and i-SENS Inc
Key Investors in Mendor
Finnvera Venture Capital
A specialized financing company owned by the State of Finland that provides loans and guarantees to strengthen the competitiveness of Finnish enterprises.
IPF Partners
A prominent alternative financing provider focused exclusively on the healthcare sector, offering tailored debt and equity solutions for medtech and biopharma companies.
i-SENS Inc
A global leader in blood glucose testing technology with extensive manufacturing capabilities and a strong market presence across 110 countries.
What's next for Mendor?
The recent influx of capital positions Mendor to scale its operations and potentially expand its footprint in the global digital health market. Given the company's history of securing both private equity and debt financing, the current lifecycle stage suggests a focus on commercial acceleration and product iteration. Future strategic initiatives are likely to center on enhancing the interoperability of their software platforms and expanding distribution networks to reach a broader international patient base. By leveraging the expertise of its institutional partners, Mendor is well-equipped to navigate the evolving regulatory and competitive landscape of the global diabetes care industry, ensuring that its technological advancements remain at the forefront of patient-centered innovation.
See full Mendor company page
